How King is Executing On Its Strategy

King is achieving its vision through an enterprise-wide focus on its core therapeutic areas, organic growth and a disciplined business development process.

King is focused on three therapeutic areas: cardiovascular/metabolics, neuroscience (especially pain products) and hospital/acute care (including drug delivery utilizing the company's auto-injector technology).

The company's strategic plan is designed to achieve long-term value for its shareholders through organic growth and business development.

Organic growth

Maximizing the potential of currently marketed products. King has a strong portfolio of core marketed products. These products provide revenue and cash flow that enable King to invest in the future of the company through the continuing development of products in the company's pipeline and business development collaborations that add innovative products and technologies to King's portfolio of products in development.

Developing pipeline products through King's R&D team King's approximately 100-person strong in-house R&D team includes drug development scientists, regulatory and drug safety staff who manage the full range of R&D activities for late-stage products: drug discovery, clinical development, drug safety, regulatory affairs, medical affairs and project management. Additionally, King has established a highly cost-effective and efficient R&D model that sets it apart from other pharmaceutical companies.

Business development

Acquiring late stage compounds and developing partnerships for promising products and technologies. King has a highly-disciplined, best-in-class business development process. Through rigorous and focused screening, King is able to identify collaborations and products most aligned with the company's strengths and strategy - to mutually benefit King, its business partners and the healthcare needs of the populations served. With a laser-focus on late stage opportunities, King has completed several collaborations involving products in development. For example, King recently entered into a strategic alliance with Pain Therapeutics for Remoxy™, an abuse-deterrent version of long-acting oxycodone, that is now under evaluation in a Phase III clinical trial.

Expanding our markets. King also seeks to expand its markets in Canada and into the European Union.